logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

The company plans to incorporate acid and neutral extracts into its soluble-gel drug delivery program

A marijuana plant
PreveCeutical says it was encouraged by tests of nasal gel sprays to administer medical-based cannabis treatments

PreveCeutical Medical Inc (CSE:PREV, OTCMKTS:PRVCF) said Tuesday it has developed a way to convert phytocannabinoids extracted from the company's five cannabis strains from acid to neutral.

The Vancouver-based company said in a press release that it has confirmed the conversion of cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) to the neutral canabidiol (CBD) and tetrahydrocannabinol (THC). It added that no degradation was detected.

HEAD: PreveCeutical encouraged by gel spray nasal delivery of cannabis-based treatments

"Having optimized the conditions for comprehensive conversion of phytocannabinoids from acid to neutral forms opens the door to a wider product range for Preveceutical,” the company's chief research officer, Dr. Harendra Parekh, said in a statement.

PreveCeutical added that it has added five neutral cannabinoid extracts to its five acid cannabinoid extracts. The company plans to incorporate acid and neutral extracts into its soluble-gel drug delivery program.

On Monday, the company said it was encouraged by tests of nasal gel sprays to administer medical-based cannabis treatments of epilepsy, anxiety and depression.

Contact Dennis Fitzgerald at [email protected]

Quick facts: PreveCeutical Medical Inc.

Price: 0.015 CAD

CSE:PREV
Market: CSE
Market Cap: $5.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 11/15/2019

2 min read